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Background: Intracranial atherosclerotic plaque causing mild luminal stenosis might lead to acute ischemic events. How-
ever, the difference between culprit and nonculprit lesions is unclear, as are the factors associated with favorable treat-
ment outcomes.
Purpose: To quantify characteristics of intracranial atherosclerosis with mild luminal stenosis and to identify factors associ-
ated with lesion type (culprit or nonculprit) and with clinical outcomes.
Study Type: Prospective
Population: 293 patients who had acute stroke with mild luminal stenosis (<50%) in the middle cerebral or basilar artery.
Field Strength/Sequence: 3.0 T higher resolution magnetic resonance imaging (hrMRI) of intracranial arteries and whole
brain MR images.
Assessment: Morphological and compositional analysis of plaques was performed. This included assessment of plaque
volume, plaque burden, remodeling ratio, eccentricity, intraplaque hemorrhage, and enhancement ratio. Clinical outcomes
were assessed according to the modified Rankin Scale (mRS) at day 90, with a favorable outcome being defined as a
90-day mRS ≤2.
Statistical Tests: The odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by a logistic regression model.
Results: Hypertension (OR 5.2; 95% CI 2.6–10.3; P < 0.05) and hrMRI enhancement ratio (OR 2.7; 95% CI 1.4–5.1;
P < 0.05) were independently associated with lesion type. Patients without hypertension had significantly more (P < 0.05)
favorable outcomes (124/144) than patients with hypertension (97/149). Most hypertensive patients without any previous
blood pressure control (54/63) had a favorable outcome. However, these patients were significantly younger (P < 0.05)
than those with adequate blood pressure control. After adjusting for all significant characteristics, hypertension duration
(OR 1.19; 95% CI 1.09–1.29; P < 0.05), hypertension management (OR 2.49; 95% CI 1.18–5.26; P < 0.05), and enhance-
ment ratio (OR 0.01; 95% CI 0.001–0.157; P < 0.05) were found to be independent high-risk factors for outcome
prediction.
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Data Conclusion: hrMRI provided incremental value over traditional risk factors in identifying higher risk intracranial ath-
erosclerosis with mild luminal stenosis.
Level of Evidence: 2
Technical Efficacy: Stage 2
J. MAGN. RESON. IMAGING 2021;54:76–88.
Intracranial atherosclerotic disease (ICAD) is a major causeof ischemic stroke worldwide, especially accounting for
40% of stroke in the Asian population.1–3 Angiology-defined
luminal stenosis remains the primary criterion for risk
assessment.4–6 Luminal stenosis >50% has been shown to be
independently associated with acute ischemic stroke.5 How-
ever, studies have revealed that lesions without significant
luminal stenosis can also lead to acute events7,8 as summa-
rized in a recent meta-analysis study in which approximately
50% of acute/subacute ischemic events were due to this type
of lesion.8 Autopsy studies have also reported that approxi-
mately 25% of fatal ischemic strokes are attributed to intra-
cranial plaques with only mild to moderate stenosis.9,10
Positive remodeling is often observed in culprit lesions
with mild stenosis where plaque grows outwards without causing
significant lumen narrowing.11 These cannot be visualized by
conventional luminal angiographic techniques such as computed
tomography angiography (CTA), MR angiography (MRA), and
digital subtraction angiography (DSA).8 Numerous studies have
demonstrated that detailed lesion morphological and composi-
tional features are more relevant to patient clinical presentations
and subsequent ischemic events than luminal stenosis alone.12–15
15 Advanced higher resolution MRI (hrMRI) is capable of visu-
alizing detailed lesion structural features, including lipid-rich
necrotic core,16 intraplaque hemorrhage (IPH),11 thin/ruptured
fibrous cap,17 and lesion inflammation.14,18 However, despite
the serious disease burden carried by intracranial atherosclerosis
with mild stenosis, most studies have focused on lesions causing
severe stenosis. Typically, studies have reported results on lesions
with mild stenosis using only a small patient cohort.19–21 The
clinical prevalence and lesion characteristics of those causing
mild stenosis therefore requires further investigation. In addition,
few studies have been carried out to identify factors associated
with clinical outcomes in patients with this type of lesion.8
Thus the aim of this prospective study was to quantify
differences in hrMRI-defined characteristics between culprit
and nonculprit intracranial atherosclerosis causing mild lumi-
nal stenosis, and to identify an optimal method to differenti-
ate lesion types and factors associated with clinical outcomes
following standard clinical management.
Methods
Study Design and Population
This study was approved by the Institutional Review Board of
Changhai Hospital of Naval Medical University (Registration
number: CHEC2018-092) and all patients provided written
informed consent. Patients attending the neurological clinic who
had acute ischemic stroke (onset within 30 days) with mild
intracranial stenosis (<50%) in one of or both middle cerebral
artery (MCA) or basilar artery (BA), determined by CTA or
MRA, were prospectively recruited from January 2013 to
December 2018. All patients received standard medical treat-
ment during hospitalization. The inclusion criteria were as fol-
lows: 1) aged 18–90 years old; 2) undergoing hrMRI
examination during hospitalization within 30 days from onset;
and 3) at least one high cardiovascular risk factor, including
hypertension, diabetes mellitus, hypercholesterolemia, or ciga-
rette smoking. Patients were excluded if they had: 1) non-
atherosclerotic intracranial arterial disease (such as vasculitis,
Moya-Moya disease, or intracranial artery dissection); 2)
suspected cardio-embolic stroke; 3) presence of notable stenosis
of the extracranial arteries (≥50%) assessed by ultrasound; 4)
presence of ascending aortic arch atheroma as identified on
MRI; 5) known coagulopathy, heart or respiratory failure; 6)
intracranial hemorrhage; 7) renal dysfunction (serum creatinine
>133 μmol/L); 8) serious disturbance of consciousness; and 9)
poor image quality assessed by three readers (one with 7 years’
experience of radiological diagnosis [Z.S.], another with 14 years’
experience [J.L.], and the other with more than 25 years’ experi-
ence [Q.L.]). The image quality including all of hrMRI images
was assessed with the following method: each slice was graded
on a 4-point scale (1 = poor; 4 = excellent) based on the overall
signal-to-noise ratio and the contrast between the vessel wall and
surrounding tissues. Images with grades ≥3 with most lumen
and outer wall boundaries visible were included in this analysis;
outer wall boundaries were manually segmented on
T2-weighted (T2W) images at sites of maximum plaque area.
Higher Resolution, Multi-Contrast Magnetic
Resonance Imaging Acquisition
The hrMRI was performed in two 3.0 T whole body systems
(GE Signa 3.0 T HDxt, GE Healthcare, Waukesha, USA; and
Skyra Siemens Healthcare, Erlangen, Germany). The GE system
was equipped with an eight-channel phased-array head coil, and
the Siemens system was equipped with a 20-channel phased array
head and neck coil. After an initial multi-plane localizer sequence,
axial three-dimensional (3D) time-of-flight (TOF) MRA was per-
formed to identify the stenosis. The hrMRI scanning parameters
for both MCA and BA were: 1) 3D TOF MRA: repetition time
(TR)/echo time (TE) = 29/3.4 msec, field of view
(FOV) = 24 × 21 cm2, slice thickness = 1.2 mm, number of
excitation (NEX) = 1, matrix = 384 × 192, sequence
July 2021 77
Shi et al.: Hypertension and Nonstenotic Atherosclerosis
duration = 4.78 minutes; 2) T2W fast spin echo (FSE): TR/
TE = 2883/50 msec, FOV = 10 × 10 cm2, NEX = 3,
matrix = 320 × 256, echo-train length (ETL) = 20, slice thickness
= 2 mm, in-plane image resolution = 0.32 mm × 0.39 mm, and
sequence duration = 3.85 minutes; 3) T1-weighted (T1W) FSE:
TR/TE = 567/16 msec, FOV = 10 × 10 cm2, NEX = 2,
matrix = 320 × 256, ETL = 6, slice thickness = 2 mm, in-plane
image resolution = 0.32 mm × 0.39 mm, and sequence dura-
tion = 5 minutes; 4) contrast enhancement T1-weighted (CE-
T1W) imaging following a dose of 0.1 mmol/kg Gd-DTPA
injected by power injector at a rate of 2 mL/sec followed by
15 mL of saline solution. Twelve slices were acquired for T1W,
T2W, and CE-T1W sequences.
MRI Data Analysis
MR data were reviewed and analyzed by three radiologists (one
with 7 years’ experience [Z.S.], another with 14 years’
experience [J.L.]), and the other with more than 25 years’ expe-
rience [Q.L.]) who were not involved in any statistical analysis.
An atherosclerotic plaque was defined as a focal wall thickening
identified on hrMRI images with or without luminal stenosis.
Each detected plaque was classified as culprit or nonculprit
referring to patient clinical presentations and findings in diffu-
sion weighted imaging (DWI) and fluid-attenuated inversion
recovery (FLAIR) images. The culprit plaque was identified as
a lesion arising on the ipsilateral side to a fresh infarction on
the DWI images with accompanying clinical symptoms. A
plaque was considered to be a nonculprit plaque when it
occurred in patients with presumed ischemic stroke/TIA but
without an infarct on DWI and FLAIR. If more than one
plaque was present in the same vascular territory, the most ste-
notic lesion was chosen for analysis (Figs. 1 and 2).
Plaque lumen and outer wall boundaries were manually
segmented on T2W images using VascularView (Nanjing
FIGURE 1: Higher resolution magnetic resonance imaging (hrMRI) images showing intracranial atherosclerotic plaque on middle
cerebral artery. A 53-year-old man with hypertension for 10 years and without previous blood pressure management having acute
ischemic stroke on the left cerebrum; TOF-MRA demonstrated a mild stenosis (<50%) located on M1 segment of left MCA, and DWI
showed a sheet acute infarcts; hrMRI images including T2WI, T1WI, and CE-T1WI at the most stenotic site visualized the outer wall
boundary (large yellow circle) and the lumen (small yellow circle), and the hrMRI parameters (minimal luminal area = 2.94 mm2; plaque
volume = 18.98 mm3; plaque burden = 76.3%; remodeling ratio = 67.1%; eccentricity index = 0.51; enhancement ratio = −5.3%) were
obtained; after hospitalizing management under high-risk factor control, he had a favorable outcome with 90 mRS being 1.
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Jingsan Medical Science and Technology, Ltd., China). The
boundary could be adjusted if necessary. The same contours
were used to analyze T1W and CE-T1W images. The degree
of luminal stenosis was measured based on TOF maximum
intensity projection using the WASID criterion.22 Minimal
luminal area (MLA) was the lumen area at the most stenotic
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and eccentricity was assumed if the index was ≥0.5. The





where S is the signal intensity at the slice of greatest enhance-
ment normalized by the signal from adjacent gray matter (in
a region of 15 mm2 at the cerebral cortex or
FIGURE 2: hrMRI images showing intracranial atherosclerotic plaque on basilar artery. A 56-year-old woman without hypertension
having acute ischemic symptom with 2 weeks; TOF-MRA showing a <50% stenosis of BA (red line on the most stenotic site) and DWI
without any fresh infarct; hrMRI images showing an eccentric plaque with the nonstenotic lumen (small yellow circle); the hrMRI
parameters (minimal luminal area = 2.71 mm2; plaque volume = 14.02 mm3; plaque burden = 78.8%; remodeling ratio = 71.1%;
eccentricity index = 0.63; enhancement ratio = 29.5%) were obtained; after standard medical management, she had achieved
0 score of the mRS at day 90.
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hippocampus).14 The enhancement ratio was classified as:
grade 0 (enhancement ratio < 15%); grade 1 (15%
≤ enhancement ratio ≤ 50%); or grade 2 (enhancement
ratio > 50%). IPH was identified if the signal intensity in a
region within the plaque was >150% of that in one of the
adjacent muscles on precontrast T1W images (Fig. 3).
The reproducibility of the image analysis was assessed
through intra- and interobserver studies. Sixty patients were
randomly selected, and images were reviewed by one reader
(**) twice with an interval of 12 weeks to avoid bias. The
same MR images were independently reviewed by another
two readers (** and **) for testing the inter-observer agree-
ment during the first time measured by the first reader.
Clinical Data Collection
Each patient underwent standard clinical management follow-
ing guidelines at admission, during the hospital stay and after
discharge. Patients’ demographics and disease history (age,
gender, smoking, diabetes, hypertension, hyperlipidemia, etc.)
and symptoms were recorded. National Institutes of Health
Stroke Scale (NIHSS; range, 0 [no symptoms] to 42 [most
severe neurologic deficits]) was recorded to assess the severity
of neurological disorder.24 The modified Rankin Scale (mRS;
range, 0 [normal] to 6 [death]), a parameter for disability
assessment, was assessed via telephone interview at 90 days
after discharge.25 A favorable outcome after medical treatment
was defined as a 90-day mRS of 0 to 2 indicating fully func-
tional independence regain, while an unfavorable outcome
was defined as a 90-day mRS of 3 to 6. The history of hyper-
tension, diabetes, hyperlipidemia, and smoking was recorded
during patient interview and by reviewing the medical
recorder. Patients with hypertension, diabetes, and hyperlipid-
emia were further grouped according to the following man-
agement types before admission: 1) no management, if the
patient did not receive any treatment; 2) partial management,
if the patient had irregular treatment/monitoring; and 3)
strict control, when the patient received treatment and moni-
toring regularly for more than 6 months.
Statistical Analysis
Statistical analyses were performed using SPSS 24.0 (IBM,
USA). Normality testing was performed to assess the variable
distribution. Univariable analysis (t-test or Mann–Whitney
U-test as appropriate for the comparison of continuous vari-
ables, and chi-squared for the comparison of categorical vari-
ables) was used to identify parameters associated with plaque
type (culprit or nonculprit) and clinical outcomes (mRS ≤2
or mRS >2). Multivariable logistic regression analysis was
then performed, which included variables with P < 0.05 in
univariate tests. The odds ratios (ORs) with 95% confidence
intervals (CIs) were calculated by a logistic regression model.
The diagnostic performance was described using receiver
operating characteristic (ROC) curves and area under curve
(AUC) values. ROC curves were compared using the method
developed by DeLong et al.26 The reproducibility of continu-
ous variables was evaluated using the intraclass coefficient
(ICC) with a two-way random-effects model, and the kappa
value was determined for the categorical variables. P-value
<0.05 was considered to be statistically significant.
FIGURE 3: The examples of plaque enhancement grade and
intraplaque hemorrhage on hrMRI. The first example is a
visualization from the basilar artery using T1WI and CE-T1WI at
the most stenotic site, which includes plaque (red arrow) and the
lumen (red star) with the enhancement grade gradually
increasing from 0 to 2. The second case shows the
hyperintensity on T1WI at the most stenotic site indicating
intraplaque hemorrhage at the basilar artery, including plaque
(red arrow) and the lumen (red star).
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Results
In total, CTA or MRA images from 446 patients with neu-
rological symptoms were reviewed, of which 43 had
dissection, 38 Moya-Moya disease, 31 aortic arch atheroma,
and 29 vasculitis. Finally, hrMRI data from 305 patients
were reviewed and 12 further patients were excluded due to
TABLE 1. Demographics and Plaque Characteristics Between Culprit and Nonculprit Lesion
Plaque Type, Mean  SD or N (%)
Total, N = 293 Culprit, N = 233 Nonculprit, N = 60 P-Value
Age (year) 59.1  10.3 58.8  10.9 60.2  7.5 0.360
Age stage
<45 years old 11 (9.1) 11 (10.5) 0 (0) 0.527
46–65 years old 71 (58.7) 61 (58.1) 10 (62.5)
>65 years old 39 (32.2) 33 (31.4) 6 (37.5)
Male 200 (68.3) 160 (68.7) 40 (66.7) 0.766
Hypertension 149 (50.9) 135 (57.9) 14 (23.3) <0.001
Diabetes mellitus 83 (28.3) 63 (27.0) 20 (33.3) 0.335
Hyperlipidemia 80 (27.3) 50 (21.5) 30 (50.0) 0.001
Smoking 113 (38.6) 89 (38.2) 24 (40.0) 0.798
NIHSS 3.2  2.5 3.3  2.7 2.6  1.3 0.038
mRS at day 90 1.8  1.2 1.9  1.2 1.3  1.2 0.001
Location
MCA 169 (57.7) 130 (55.8) 39 (65.0) 0.198
BA 124 (42.3) 103 (44.2) 21 (35.0)
Enhancement ratio (%) 18.2  20.1 16.2  20.9 9.8  14.2 <0.001
Enhancement grade
Grade 0, <15% 109 (37.2) 84 (36.1) 25 (41.7) 0.035
Grade 1, 15%–50% 151 (51.5) 116 (49.8) 35 (58.3)
Grade 2, >50% 33 (11.3) 33 (14.2) 0 (0)
Stenosis (%) 34.8  11.4 34.9  11.3 34.7  11.7 0.944
Intraplaque hemorrhage 44 (15.0) 43 (18.5) 1 (1.7) 0.001
MLA (mm2) 3.7  3.1 3.9  3.3 2.7  1.8 0.005
Plaque volume (mm3) 30.8  16.8 32.3  18.1 24.8  8.1 0.002
Plaque burden (%) 76.6  11.3 76.3  10.9 77.9  12.5 0.330
Remodeling ratio (%) 110.2  49.1 112.7  53.6 100.7  22.9 0.093
Remodeling type
Positive remodeling 132 (53.7) 100 (50.8) 32 (65.3) 0.068
Negative remodeling 114 (46.3) 97 (49.2) 17 (34.7)
Eccentricity 196 (66.9) 160 (68.7) 36 (60.0) 0.203
The bold numbers represented P-value <0.05.
BA = basilar artery; MCA = middle cerebral artery; MLA = minimum luminal area; mRS, modified Rankin Scale; NIHSS = National
Institutes of Health Stroke Scale.
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poor image quality. hrMRI data from 293 patients
(59.1  10.3 years old; 200 males) were eventually
included in the study and analyzed. The patient demo-
graphics are listed in Table 1. One hundred and sixty-nine
lesions were located in the MCA with 130 being culprit,
and 124 in the BA with 103 being culprit. At discharge,
the mRS was 1.4  1.1. Two hundred and twenty-one
(75.4%) patients had a favorable outcome after treatment
(mRS ≤2) whereas 72 cases had an unfavorable outcome
(mRS >2) at day 90.
In the following sections, the difference in high risk
factors and lesion characteristics between culprit and non-
culprit lesions was first analyzed, followed by patient
cohort with different treatment outcome, and finally
factors associated with unfavorable outcomes were
identified.
Patient Demographics, Plaque Characteristics, and
Lesion Type
As summarized in Tables 1 and 3, the univariable analyses
showed that hypertension, hypertension management, hyper-
lipidemia, NIHSS, enhancement ratio, enhancement grade,
plaque volume, MLA, and presence of IPH were significantly
associated with culprit lesions (all P < 0.05). Multivariable
logistic regressions confirmed that hypertension (OR 5.2;
95% CI 2.6–10.3; P < 0.05) and enhancement ratio
(OR 2.7; 95% CI 1.4–5.1; P < 0.05) were strongly associated
with culprit plaques. Compared with hypertension alone
(AUC =0.683 [95% CI 0.599–0.747]) or enhancement ratio
alone (AUC =0.671 [95% CI 0.593–0.721]), the combina-
tion of these two factors improved the AUC to 0.829 (95%
CI 0.772–0.886; P < 0.05) with sensitivity and specificity
being 0.861 and 0.792, respectively (Fig. 4a).
FIGURE 4: ROC curves as well as OR and 95% CI on the basis of multivariable logistic regression to (a) differentiate culprit from
nonculprit lesions; (b) predict the favorable outcomes from unfavorable ones.
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TABLE 2. Univariable and Multivariable Analysis on Clinical Outcome After Medical Management
Univariable Analysis,












Age 58.2  10.0 61.9  10.9 0.012 0.95 (0.85–1.06) 0.377
Male 149 (67.4) 51 (70.8) 0.589
Hypertension 97 (43.9) 52 (72.2) <0.001 2.79 (1.47–5.29) 0.051
Hypertension duration 4.5  6.2 13.6  11.1 <0.001 1.19 (1.09–1.29) <0.001
Hypertension management
No control 54 (55.7) 9 (17.3) <0.001 2.49 (1.18–5.26) 0.017
Partial control 37 (38.1) 21 (40.4)
Strict control 6 (6.2) 22 (42.3)
Diabetes mellitus 72 (32.6) 11 (15.3) 0.005 0.57 (0.15–2.14) 0.406
Diabetes duration 5.0  6.3 4.1  8.4 0.297
Hyperlipidemia 65 (29.4) 15 (20.8) 0.156
Hyperlipidemia duration 2.4  3.6 2.2  5.1 0.701
Smoking 92 (41.6) 21 (29.2) 0.059
Smoking duration 8.2  10.9 10.7  18.3 0.172
NIHSS 3.2  2.5 3.2  2.4 0.989
Location, N (%)
MCA 119 (53.8) 50 (69.4) 0.020
BA 102 (46.2) 22 (30.6)
hrMRI characteristics
Enhancement ratio (%) 19.8  20.1 13.1  19.2 0.011 0.01 (0.001–0.157) 0.001
Enhancement grade
Grade 0, <15% 67 (30.3) 42 (58.3) <0.001 0.28 (0.07–1.17) 0.081
Grade 1, 15%–50% 129 (58.4) 22 (30.6)
Grade 2, >50% 25 (11.3) 8 (11.1)
Stenosis (%) 35.1  11.8 33.9  9.9 0.462
Intraplaque hemorrhage 32 (14.5) 12 (16.7) 0.652
MLA (mm2) 3.9  3.2 3.1  2.5 0.040 1.34 (1.00–1.78) 0.067
Plaque volume (mm3) 31.9  17.7 27.5  13.3 0.029 0.97 (0.94–1.01) 0.056
Plaque burden (%) 75.3  11.7 80.7  8.7 0.001 28.7 (13.0–63.2) 0.104
Remodeling ratio (%) 107.1  40.8 119.7  68.2 0.059
Remodeling type
Positive remodeling 105 (56.5) 27 (45.0) 0.122
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Patient Demographics, Plaque Characteristics, and
Clinical Outcomes
Although most of the acute symptomatic patients with mild
intracranial stenosis had favorable outcomes (N = 221,
75.4%), 24.6% (N = 72; 63 culprit) had a poor outcome
with mRS ≥2 at 90 days after discharge (Table 2).
Univariable analysis indicated that hypertensive patients with
favorable outcomes had shorter duration of hypertension than
those with unfavorable outcomes (5.2  6.2 vs. 12.9  10.7;
P < 0.05). As with plaque type, significant differences in
plaque volume, plaque burden, MLA, remodeling ratio, and
enhancement ratio were found between these two groups (all
P < 0.05). Moreover, patients with nonstrict control of blood
pressure, lower plaque enhancement grade, and eccentric
lesions had significantly more unfavorable out-
comes (P < 0.05).
The multivariable logistic regression showed that only
hypertension duration (OR 1.24; 95% CI 1.12–1.37;
P < 0.05), hypertension management (OR 2.53; 95% CI
1.13–5.68; P < 0.05), and enhancement ratio (OR 0.015;
95% CI 0.001–0.105; P < 0.05) were independent high-risk
factors to predict the clinical outcomes. The AUCs were
0.789 (95% CI 0.700–0.870), 0.751 (95% CI
0.650–0.831), and 0.682 (95% CI 0.575–0.769), respec-
tively (Fig. 4b). When combined, the AUC increased to
0.925 with accuracy, sensitivity, and specificity being 0.859,
0.874, and 0.825, respectively. The diagnostic performance is
shown in Table 3.
If only patients with culprit lesion (N = 233) were con-
sidered, it remained nearly the same that hypertension dura-
tion and management together with lesion enhancement ratio
were key determinants associated with clinical outcome
(170 had favorable outcome and 63 unfavorable). The quan-
titative comparisons between these two groups were provided
in Table S1.
Hypertension, Hypertension Management, and
Clinical Outcomes
In the present study, 149 patients suffered from hypertension
and culprit lesions were found in 135 of them. Only 9.6% of
these patients (N = 28) were subject to strict blood pressure
control. Patients without any previous control were younger
than those with partial or strict control (55.5  7.9
vs. 66.9  10.5 or 64.0  5.3; unit: year; both P < 0.05)
(Table 4). In contrast, significantly more (P < 0.05)
patients without hypertension had a favorable outcome
TABLE 2. Continued
Univariable Analysis,








N = 72 P-Value
Odds ratio
(95% CI) P-Value
Negative remodeling 81 (43.5) 33 (55.0)
Eccentricity 131 (59.3) 65 (90.3) <0.001 3.3 (0.9–11.9) 0.073
The bold numbers represented P-value <0.05.
hrMRI = higher resolution magnetic resonance imaging; MLA = minimal luminal area; mRS = modified Rankin Scale;
NIHSS = National Institutes of Health Stroke Scale.
TABLE 3. The Diagnostic Performance of Logistic Regressions
ROC AUC DA Sensitivity Specificity PPV NPV LR− LR+
Lesion type
Mode 0.829 0.839 0.861 0.792 0.897 0.731 4.135 0.175
Clinical outcome
Mode 0.925 0.859 0.874 0.825 0.922 0.733 4.992 0.153
DA = diagnosis accuracy; LR− = negative likelihood ratio; LR+ = positive likelihood ratio; NPV = negative predictive value;
PPV = positive predictive value.
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(124/144) than patients with hypertension (97/149). For
those without any previous control (N = 63), 86% (54/63)
achieved functional independence (mRS 0–2) after standard
blood pressure lowering therapy, while only 64% patients
in the group with partial control (37/58) had a favorable
clinical outcome. On the contrary, only 21% (6/28)
patients with a previous strict blood pressure control had a
favorable outcome.
Furthermore, in the 28 patients with a previous strict
blood pressure control, 22 had an unfavorable outcome, as
shown in Table 4. As shown in Fig. 5, of these 22 patients,
lesions in 15 patients did not show any enhancement, five
had IPH, eight had positive remodeling, and 20 were eccen-
tric. In those with a partial blood pressure control (N = 58),
21 patients achieved a poor outcome. In these 21 patients,
19.0% (N = 4) had IPH, 42.9% (N = 9) had positive remo-
deling, 47.6% (N = 10) showed no enhancement and 95.2%
(N = 20) were eccentric. Only nine cases in the subgroup
having no hypertensive control achieved an unfavorable out-
come. In these, hrMRI showed all plaques were without IPH,
six cases were without enhancement, four cases were eccen-
tric, and two showed positive remodeling.
TABLE 4. Comparison of the Clinical and Plaque Characteristics in Hypertension Management
Hypertension Management, Mean  SD or N (%)
No Control, N = 63 Partial Control, N = 58 Strict Control, N = 28 P-Value
Age stage (year) 55.5  7.9 66.9  10.5 64.0  5.3 <0.001
Males 53 (84.1) 42 (72.4) 15 (53.6) 0.009
Culprit plaque 62 (98.4) 53 (91.4) 20 (71.4) <0.001
Unfavorable outcome 9 (14.3) 21 (36.2) 22 (78.6) <0.001
Enhancement ratio (%) 21.7  17.6 21.4  21.4 12.9  29.9 0.173
No enhancement 16 (25.4) 20 (34.5) 17 (60.7) 0.003
Intraplaque hemorrhage 6 (9.5) 4 (6.9) 6 (21.4) 0.115
Stenosis ratio (%) 37.6  11.9 31.9  8.8 41.1  6.1 <0.001
MLA (mm2) 3.1  2.3 3.8  3.3 3.2  2.8 0.275
Plaque volume (mm3) 30.9  16.8 31.3  21.8 29.3  12.9 0.890
Plaque burden (%) 76.8  12.3 78.9  9.5 79.3  11.0 0.490
Remodeling ratio (%) 113.6  68.4 106.6  51.8 120.6  52.3 0.580
Positive remodeling 17 (35.4) 22 (43.1) 11 (57.9) 0.242
Eccentricity 12 (40.0) 24 (77.4) 10 (83.3) 0.002
MLA = minimal luminal area.
FIGURE 5: The frequency distribution of the patients with unfavorable outcome on the subgroups of hypertension management with
different hrMRI features (no enhancement, IPH, positive remodeling, and eccentricity.
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Reproducibility of hrMRI Analysis
The reliability of hrMRI for the identification of morphologi-
cal and compositional features in ICAD was assessed through
the intra- and interobserver agreement analysis. The intra-
and interobserver agreements for all variables were excellent.
The ICCs of the intra- and interobserver agreement were
shown in Table S2. The ICC of intraobserver agreement was
0.89  0.01 and that of interobserver agreement was
0.91  0.02. The kappa values for IPH identification and
eccentricity calculation were 0.92 and 0.90, respectively.
Discussion
This study revealed a prevalence of about a third (293/967) of
intracranial atherosclerotic plaque without substantial stenosis
in symptomatic patients (967 is the number of total patients
with acute ischemic symptom refers to all of the patients
underwent hrMRI with mild to substantial stenosis). Logistic
regression analysis indicated that hypertension and plaque
enhancement ratio were two independent factors strongly asso-
ciated with culprit lesions and clinical treatment outcomes;
patients without a history of hypertension were found to be
very likely to have a nonculprit plaque and a good outcome.
For those with uncontrolled or partially controlled hyperten-
sion, the standard treatment protocol for risk management was
effective. However, the current standard treatment strategy was
insufficient for patients with previous strict blood pressure con-
trol who had predominantly unfavorable outcomes.
It has been widely reported that hypertension plays an
important role in the development of atherosclerosis, which
might eventually result in occlusive and artery-to-artery
embolic strokes.27–29 Although hypertensive patients with
nonstenotic ICAD may have a higher rate of unfavorable out-
come compared with those without hypertension, the dura-
tion of hypertension and previous management are additional
important predictors of outcome when adjusting for all other
high-risk factors, including: age; diabetes mellitus; NIHSS;
and hrMRI-defined plaque features (such as enhancement
ratio, enhancement grade, remodeling ratio, and eccentricity).
It was found that the longer the duration of the hypertensive
status, the higher the incidence of an unfavorable outcome.
The possibility of an unfavorable outcome among the indi-
viduals with hypertension may be nearly three times than that
among nonhypertensive patients (OR = 2.79). The findings
remained valid in symptomatic patients with culprit lesions,
that is, the hypertension and enhancement ratio were also key
determinants for clinic outcome for those with culprit lesions.
This implies that the current standard clinical manage-
ment for these patient cohorts might be improved by
accounting for systematic chronic damage induced by high
blood pressure. A longer duration of hypertension might
induce more damage to the small cerebral arteries and to
nearby brain tissues. It is also possible that unidentified high-
risk factors develop within the period when the blood pres-
sure management is applied and hypertension occurs. Unfa-
vorable outcomes were more likely to occur in a hypertensive
cohort with previous strict control than in a cohort without
any control. This does not mean that previous strict blood
pressure control leads to an unfavorable outcome. On the
contrary, our findings may have demonstrated the benefit of
previous blood pressure control as it may have postponed
symptom occurrence. And it was evidenced by the fact that
patients without any control were over 10 years younger than
those with. High blood pressure with inadequate previous
management was likely the main cause of symptoms for this
younger patient cohort, and therefore the standard blood
pressure lowering clinical treatment was effective.
In addition to hypertension, hrMRI provided comple-
mentary information to assist in differentiating lesion type
and in predicting clinical outcomes. Culprit lesions tended to
have a higher enhancement ratio, higher prevalence of IPH,
smaller MLA, and larger plaque volume than the nonculprit
lesions. Unfavorable outcomes were associated with lower
enhancement ratio, smaller MLA and plaque volume, higher
plaque burden, and larger eccentricity index. Enhancement
ratio is a parameter reflecting local inflammation or edema as
results of plaque rupture that could be reduced by treatment
in the short term.30 It is possible that the standard treatment
reduced the inflammation effectively in 3 months, while
lesion geometric factors such as remodeling ratio and eccen-
tricity were more resistant to the medical management.
hrMRI was also useful in predicting clinical outcome in sub-
group analysis in patients with hypertension.
According to the trial of ORG 10172 in acute stroke
treatment (TOAST) classification,31 patients with nonstenotic
ICAD and without other identifiable lesions are considered as
cryptogenic stroke or embolic stroke of undetermined source
(ESUS) rather than large artery atherosclerosis stroke. How-
ever, advanced hrMRI might provide the embolic source
responsible for the symptoms as positive remodeling might
exist in nonstenotic lesions32 that are not identifiable by con-
ventional angiography including MRA, CTA, and DSA.
Numerous studies7-14,16–21 have described the association of
various plaque characteristics including plaque morphology
(such as plaque volume, plaque burden, MLA, remodeling),
compositional features (such as IPH) and enhancement with
acute stroke in general, regardless of the degree of luminal ste-
nosis. Researchers have reported an urgent need to differenti-
ate nonstenotic atherosclerosis from ESUS for optimal
treatment and prevention strategies.33 A recent systematic
review8 showed that over half of ischemic stroke patients
without significant stenosis might have a culprit intracranial
plaque identifiable on hrMRI. Moreover, the discrepancy
between hrMRI and conventional angiography such as MRA
was particularly evident in patients with mild stenosis,
suggesting that hrMRI is more sensitive for detecting early
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ICAD.34,35 hrMRI allows for the characterization of high-risk
plaques that can be used to identify culprit lesions more
accurately,36 especially using gadolinium contrast enhance-
ment within the plaque which has been shown to correlate
with fibrous cap inflammation and rupture, as confirmed in
histological specimens.17 Results obtained in this study are in
agreement with previous studies in that atherosclerotic
plaques in the vessel supplying the infarction territory may
show strong enhancement.14,18
Limitations
Prehospitalization information on management of diabetes
and hyperlipidemia was not available and analysis on these
aspects was therefore not performed. Although these factors
might contribute to the differentiation of lesion type and
treatment outcome, compared with hypertension, far fewer
patients in this study had diabetes and hyperlipidemia. More-
over, there was no significant difference in the distribution of
patients with diabetes or hyperlipidemia between the groups
with different type lesions or different clinic outcomes. Fur-
thermore, 28 patients had both diabetes and hypertension,
while 27 patients had hyperlipidemia and hypertension,
though none of the patients had all three characteristics. Glu-
cose and lipid levels in these patients should be managed fol-
lowing the same pattern as the blood pressure. Therefore, the
missing information of the prehospitalization management of
diabetes and hyperlipidemia should have a limited impact on
the conclusions of this study. Further study limitations
include: 1) this was a single-center study limited to Chinese
populations; 2) our analysis was performed using two-
dimensional imaging data. It is possible that the thinner slices
that could be achieved with 3D imaging could allow better
characterization of plaque features by reducing partial volume
effects; 3) longer follow-up should be performed to ensure
the effectiveness of the current treatment strategy in patients
with unfavorable outcomes in 3 months; and 4) patients
might not remember their exact history of blood pressure
management and the uncertainty in the classification of blood
pressure control might exist.
Conclusions
Hypertension and plaque enhancement were two indepen-
dent factors strongly associated with culprit lesions and clini-
cal treatment outcomes. hrMRI provided incremental value
over traditional risk factors in identifying higher risk intracra-
nial atherosclerosis with mild luminal stenosis. And current
standard clinical management might be sub-optimal for the
patients with previous strict blood pressure control.
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